Events

2016 News Releases



Webcast ImageWebcast
Q1 2017 Rigel Pharmaceuticals Inc. Earnings Conference Call  (Live)
May 2, 2017 at 2:00 p.m. PT
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/10/16Rigel to Present at Jefferies 2016 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16th at 11:20am GMT.  To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior ... 
 Printer Friendly Version
11/01/16Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2016. During the third quarter of 2016, Rigel accomplished a number of noteworthy milestones, most importantly, the announcement of topline results for its FIT Phase 3 clinical studies of fostamatinib in ITP. Additionally, the company undertoo... 
 Printer Friendly Version
10/28/16Rigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2016 financial results after the stock market closes on Tuesday, November 1, 2016.  Members of Rigel's senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 ... 
 Printer Friendly Version
10/20/16Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP
Conference call and webcast today at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Oct. 20, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced results for the second of two double-blind studies in the FIT Phase 3 clinical program for fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in adult chronic/persistent immune thrombocytopenia (ITP).  The primary endpoint in the study was a stable platelet response, defined as platelet counts greater than 5... 
 Printer Friendly Version
10/07/16Rigel Expands Leadership Team in Research and Business Development
Reaffirms research focus and IRAK program plans SOUTH SAN FRANICSCO, Calif., Oct. 7, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced the appointment of two company veterans to leadership roles that will impact Rigel's newly refocused small molecule R&D effort targeting immunology and oncology diseases.  Esteban Masuda, Ph.D., who has made significant contributions to Rigel's research programs for 18 years, has been named Senior Vice President, Research. Joseph ... 
 Printer Friendly Version
09/15/16Rigel Restructures to Focus on Fostamatinib Commercialization
Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for the treatment of chronic immune thrombocytopenia (ITP). The company recently reported that fostamatinib met the primary endpoint in the first of two identical Phase 3 studies in chro... 
 Printer Friendly Version
08/30/16Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
Conference call and webcast today at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP).  The study (n=76) showed that 18% of patients receiving fostamatinib achi... 
 Printer Friendly Version
08/29/16Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) on Tuesday, August 30, 2016.  The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 study results. Participants can access the... 
 Printer Friendly Version
08/02/16Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2016. "We look forward to announcing the topline results for the first of two Phase 3 studies of fostamatinib in patients with ITP by the end of this August, followed by the second study's results a few months later," said Raul Rodriguez, president... 
 Printer Friendly Version
07/26/16Rigel Announces Conference Call and Webcast to Report Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., July 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2016 financial results after market close on Tuesday, August 2, 2016.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-293... 
 Printer Friendly Version
06/02/16Rigel to Present at Jefferies 2016 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 10:30 am ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live web... 
 Printer Friendly Version
05/05/16Rigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 5, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present three scientific posters at the American Association of Immunologists (AAI) meeting in Seattle, Washington from May 13-17, 2016.  The posters provide data from the company's preclinical research programs in key anti-inflammatory and autoimmune targets, Nrf2, MerTK and IRAK1/4. Rigel plans to partner select preclinical research programs in the future. An ove... 
 Printer Friendly Version
05/03/16Rigel Announces First Quarter 2016 Financial Results
- Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., May 3, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016. "We look forward to our upcoming Phase 3 data as we continue with our planning for the potential commercial launch of fostamatinib in the United States," said Raul Rodriguez, president and chief executive officer of Rigel.  "Also, we initiated the Phase ... 
 Printer Friendly Version
04/26/16Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., April 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (... 
 Printer Friendly Version
04/12/16Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference
SOUTH SAN FRANCISCO, Calif., April 12, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will present three scientific posters at the American Association of Cancer Research meeting in New Orleans, Louisiana from April 16 - 20, 2016.  The posters will provide data from the company's preclinical research projects focused on the important oncology and immuno-oncology targets, IRAK, AMPK and MerTK. Rigel plans to partner select preclinical research programs in t... 
 Printer Friendly Version
04/01/16Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., April 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromboycytopenic purpura (ITP).  The first study in this program completed enrollment at the end of January and the second study has now completed enrollment.  The results from the first study are expected in the middle of 20... 
 Printer Friendly Version
03/08/16Rigel Announces Fourth Quarter and Year End 2015 Financial Results
- Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., March 8, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2015. "Fostamatinib is our top priority for 2016 with the first results of our Phase 3 studies in immune thrombocytopenic purpura anticipated in the middle of the year," said Raul Rodriguez, president and chief executive officer of Rigel.  "Also... 
 Printer Friendly Version
03/08/16Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program SOUTH SAN FRANCISCO, Calif., March 8, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Anne-Marie Duliege, M.D., M.S. to the role of chief medical officer, replacing Elliott Grossbard, M.D., who is retiring from that position after 14 years with the company.  Dr. Grossbard will remain with the company, advising on the new drug application (NDA) filing and ... 
 Printer Friendly Version
03/01/16Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., March 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2015 financial results after market close on Tuesday, March 8, 2016.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or... 
 Printer Friendly Version
02/29/16Rigel to Present at Cowen and Company 36th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Monday, March 7th at 2:40 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start o... 
 Printer Friendly Version
02/25/16Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2016 /PRNewswire/ -- Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).  The purpose of this clinical trial is to evaluate the safety and efficacy of fostamatinib in patients with chronic AIHA. This disorder affects an estimated 40,000 Americans, for whom no approved treatment options current... 
 Printer Friendly Version
01/28/16Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune thrombocytopenic purpura (ITP) completed patient enrollment this month. The results from this first study are expected in the middle of 2016, with the results from the second study expected shortly thereafter.  The FIT program consists of two identical studies of 75 patients each. The patients will have ... 
 Printer Friendly Version
01/07/16Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 14 at 9:30 a.m. Pacific Time (see webcast details below). Rigel's presentation will include a fostamatinib program update, including ... 
 Printer Friendly Version